Efficiently develop antibody-based therapeutics
Drug Discovery World
OCTOBER 12, 2022
In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing. . Approaches for monoclonal antibody formulation .
Let's personalize your content